TP53 and cancer: Then, a correlation between NRF2 expression and reduced HIPK2 activity in colon cancer cells was found in pre-clinical studies showing that NRF2 activation correlates with the inhibition of phosphorylation of p53Ser46 and with the reduction of cisplatin-induced cell death, highlighting an interplay between NRF2 and HIPK2/p53 axis in response to anticancer chemotherapy that can be hijacked by cancer cells to bypass drug cytotoxicity [43,44].